Marker Therapeutics, Inc. — Director's Dealing 2015

Nov 13, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2011-02-16

Reporting Person: WILSON GLYNN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-02-26	Common Stock	J	513319	$0.80	Acquired	525457	Direct
2014-12-02	Common Stock	A	120000	$1.00	Acquired	645457	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-02-16	Employee Stock Option (Right to Buy	$17.00	A	1600	Acquired	2021-02-16	Common Stock (1600)	Direct

Footnotes

F1: Represents common shares issued by the Company in exchange for cancellation of amounts owed to Dr. Wilson of $410,655 in connection with the Company's restructuring in early 2014 in which Series A preferred was issued for the debt and subsequently converted into the common stock.

F2: Represents shares issued by the Company to Dr. Wilson in satisfaction of compensation owed to Dr. Wilson in the amount of $120,000.

F3: These options were originally issued prior to the Company's most recent February 2014 1 for 100 reverse split and amounts reflected are on a post-split basis. The shares have vested.

F4: Represent current derivative securities owned including the instant award reported hereby.